Abstract
Boston-based Decibel Therapeutics has raised $55 million in series C financing to continue developing therapies to treat hearing loss and tinnitus. The start-up is working on two compounds to protect against hearing loss that is a side effect of other drugs and on a gene therapy to restore hearing. George Scangos, CEO of Vir Biotechnology and former CEO of Biogen, now heads Decibel’s board of directors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
